Advanced Filters
noise

solid-tumors Clinical Trials

A listing of solid-tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,608 clinical trials
L Li Zhang, professor

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a variety of solid tumors, including small cell lung cancer, multiple myeloma, and neuroblastoma, and hematological malignancies.

18 years of age All Phase 1

A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.

18 - 75 years of age All Phase 1
Y Yuankai Shi, MD

A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors

CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.

18 years of age All Phase 1

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.

18 - 80 years of age All Phase 1

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.

18 - 75 years of age All Phase 1/2
Y Yan Shi

Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors. The primary objectives of the study are to assess safety and tolerability of TI-0093 injection in patients with recurrent or …

18 - 75 years of age All Phase 1
S Scott C Lester, M.D.

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Eligible participants have stage 4 metastatic solid tumor(s), that is(are) not responding to conventional treatment or have declined …

18 years of age All Phase N/A
F Feng'e Li

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

18 years of age All Phase 1
T Trong Nguyen

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize …

18 years of age All Phase 1
S Study Coordinator

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid …

18 years of age All Phase 1/2

Simplify language using AI